Paper Details

  1. Home
  2. Paper Details

Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Author: BombardieriE, BottaF, Carlo-StellaC, ChiesaC, ColivaA, DevizziL, GianniM A, GuidettiA, MaccauroM, SeregniE

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Using 45 MBq/kg of (90)Y-ibritumomab tiuxetan in association with stem cell autografting resulted in patients being free of toxicity in non-haematological organs. These findings were consistent with dose estimations considering both organ doses and BED values.
Paper Details　
Original Abstract of the Article :
PURPOSE: The aim of this study was to carry out two different dose estimation approaches in patients with non-Hodgkin's lymphoma (NHL) treated with a myeloablative amount of (90)Y-labelled ibritumomab tiuxetan (Zevalin(R)) in an open-label dose escalation study. METHODS: Twenty-seven patients with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00259-009-1141-x

データ提供：米国国立医学図書館（NLM）

High-Activity Myeloablative 90Y-ibritumomab Tiuxetan: A Powerful Weapon in the Desert of Lymphoma

Non-Hodgkin's lymphoma, a cancer of the lymphatic system, can be a daunting journey through the desert of disease. This study, like a camel caravan armed with a powerful weapon, investigates the use of high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin), a targeted therapy that delivers radioactive isotopes to lymphoma cells, in the treatment of high-risk non-Hodgkin's lymphoma. Researchers evaluated the absorbed dose and biologically effective dose in patients receiving myeloablative doses of 90Y-ibritumomab tiuxetan, followed by stem cell transplantation. The study found that the treatment was well-tolerated, with minimal acute hematological toxicity and no evidence of secondary malignancy or treatment-related myelodysplastic syndrome. The study also found that the absorbed doses were within acceptable limits, suggesting that this treatment approach can effectively target lymphoma cells while minimizing damage to healthy tissues.

A Promising Path in the Desert of Lymphoma

This research highlights the potential of high-activity myeloablative 90Y-ibritumomab tiuxetan as a powerful weapon in the fight against high-risk non-Hodgkin's lymphoma. The study's findings suggest that this treatment approach can achieve significant therapeutic effects with a favorable safety profile, offering a potential oasis for individuals battling this challenging cancer.

Navigating the Desert of Cancer

Non-Hodgkin's lymphoma is a complex disease, and managing it effectively requires a multi-faceted approach. Working closely with a healthcare professional to develop an individualized treatment plan, including medications, supportive care, and lifestyle modifications, is crucial for navigating the desert of cancer.

Dr. Camel's Conclusion

High-activity myeloablative 90Y-ibritumomab tiuxetan emerges as a powerful weapon in the arsenal of treatments for high-risk non-Hodgkin's lymphoma. This study, like a camel discovering a hidden spring in the desert, offers a glimmer of hope for individuals seeking relief from this challenging disease.
Date :
  1. Date Completed 2010-05-14
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

19455328

DOI: Digital Object Identifier

10.1007/s00259-009-1141-x

Related Literature

Article Analysis
・Effects of ibritumomab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.